Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Geriatrics›Condition·Updated Jul 11, 2026·v1

Frailty Syndrome

Frailty syndrome is a prevalent, potentially reversible geriatric condition marked by decreased physiological reserve and vulnerability to stressors. Diagnosis relies on validated instruments (Fried Phenotype, Frailty Index, Clinical Frailty Scale). Management is multimodal, combining exercise (mind-body or multicomponent), individualized nutritional support (NNT=16 for mortality reduction), deprescribing, and fall prevention. No pharmacologic agent is approved. Early identification and intervention can prevent progression to disability and death.

Moderate Evidence101 references·2,145 words·9 min read·v1
frailtygeriatricscomprehensive geriatric assessmentsarcopeniainflammaging

Quick Reference

RxDrug of choiceNone; multimodal non-pharmacologic therapy (exercise, nutrition, deprescribing) is first-line.
AltAlternativesNeuromuscular electrical stimulation (NMES) as adjunct when active exercise is not possible.
⊘AvoidAvoid testosterone, growth hormone, vitamin D alone, and anti-inflammatory drugs for frailty treatment, no evidence of benefit and potential harm.
DxTest of choiceComprehensive Geriatric Assessment (CGA) is gold standard; Clinical Frailty Scale (CFS) for bedside screening; Fried Phenotype or Frailty Index for confirmation.
ScKey scoreClinical Frailty Scale (CFS) >4 or Fried Phenotype ≥3; pre-frailty = 1-2 Fried criteria.
→When to referRefer to geriatrician for CGA and multidisciplinary management when frailty is confirmed or when pre-frailty is identified (to prevent progression).
Frailty is a common, potentially reversible geriatric syndrome; early screening with CFS, confirmation by Fried Phenotype or FI, and multimodal non-pharmacologic intervention (exercise, nutrition, deprescribing) reduce mortality (NNT=16 for nutritional support) and prevent functional decline.
Frailty syndrome is a geriatric condition of decreased physiological reserve, increasing vulnerability to falls, hospitalization, disability, and mortality. It is distinct from normal ageing and multimorbidity, but frequently coexists. Early identification using validated tools (e.g., Fried Phenotype, Clinical Frailty Scale) is critical because frailty is potentially reversible with multimodal interventions including exercise, nutrition, and deprescribing. This concise reference summarizes key clinical facts, screening, diagnosis, management, and prognosis for bedside use.

Overview and Recommendations

Background

  • •Frailty syndrome is a geriatric condition of decreased physiological reserve across multiple organ systems that increases vulnerability to stressors, predicting falls, hospitalization, disability, and mortality. It is distinct from normal ageing and disability, although these frequently coexist.
  • •Prevalence is 10-15% in community-dwelling adults aged ≥65 years and rises steeply with age. Frailty is an independent predictor of adverse outcomes surpassing chronological age alone, and is potentially reversible if identified early.
  • •Two principal diagnostic constructs guide classification: the Fried Phenotype (≥3 of 5 criteria: unintentional weight loss, exhaustion, weakness, slow gait, low activity; 1-2 criteria define pre-frailty) and the Frailty Index (deficit accumulation ratio >0.25). The Clinical Frailty Scale (CFS) is a 9-point bedside tool for rapid risk stratification.
  • •The pathophysiology centers on inflammaging (chronic low-grade IL-6, TNF-α elevation) driven by NLRP3 inflammasome activation, mitochondrial dysfunction, stem cell exhaustion, epigenetic drift (FOXO3A downregulation), and gut microbiota dysbiosis with tryptophan-kynurenine pathway shunting. These self-reinforcing pathways cross a critical threshold, rendering single-target interventions ineffective.
  • •Frailty is embedded within a network of interdependent geriatric syndromes, falls, delirium, incontinence, immobility, pressure injury, that share common risk factors and cascade together. An acute stressor can trigger a downward spiral that early recognition and multimodal intervention can interrupt.

Evaluation

  • •Suspect frailty in any older adult (≥70 years, or ≥65 with significant comorbidity) who presents with weakness, slowing down, unintentional weight loss, exhaustion, recurrent falls, or simply "failure to thrive." Weakness is the most common first manifestation, preceding other criteria in 76% of women who become frail.
  • •Ask about difficulty rising from a chair, carrying groceries, walking speed, and self-reported exhaustion ("everything is an effort"). Document weight changes over the past year, quantify physical activity using standardized questionnaires, and screen for depressive symptoms with the Geriatric Depression Scale.
  • •Examine for objective signs: measure grip strength with a hand dynamometer (lowest 20% adjusted for sex and BMI defines weakness), assess gait speed over 4 meters (threshold <0.8 m/s for slowness), and observe chair rise ability, ability to stand from a chair without arms is a favorable prognostic sign.
  • •Screen for unintentional weight loss ≥5% in the prior year from records or serial weights. Document low physical activity using validated tools like the Minnesota Leisure Time Activities questionnaire.
  • •Administer the Clinical Frailty Scale (CFS) as a rapid bedside screen, score >4 (vulnerable or frail) warrants further evaluation and triggers delirium prevention in acute care. A score CFS >4 combined with age >85 years and invasive devices explains 95% of delirium cases.
  • •Confirm frailty using the Fried Phenotype (≥3 of 5 criteria positive) or compute a Frailty Index (≥0.25) from accumulated deficits. Pre-frailty (1-2 Fried criteria) is a critical window for intervention as it is high-risk for progression yet responsive to simple lifestyle changes.
  • •Once frailty is confirmed, perform a Comprehensive Geriatric Assessment (CGA), the gold-standard definitive workup, evaluating medical (multimorbidity, polypharmacy, nutrition, sensory deficits), functional (ADLs, mobility, Timed Up and Go test), cognitive (MMSE, MoCA), and psychosocial domains (mood, social support, caregiver burden).
  • •Order basic labs to rule out reversible contributors: CBC, comprehensive metabolic panel, TSH, vitamin B12, vitamin D. If weakness is prominent or rapidly progressive, check creatine kinase (CK >1000 U/L suggests myositis or an alternative diagnosis such as anti-HMGCR myopathy).
  • •Assess for coexisting geriatric syndromes: falls risk (gait speed, chair rise), delirium (acute onset of confusion), urinary incontinence, and pressure injury risk (Braden scale). Screen for cognitive impairment and depression in every patient presenting with frailty features.
  • •Red flags for alternative diagnoses: rapid progression over weeks, new focal neurological signs, or markedly elevated CK should prompt investigation for myositis, malignancy, or other primary neuromuscular disease that may mimic or accelerate frailty.

Management

  • •Initiate multimodal rehabilitation as the foundation of frailty management: prescribe a multicomponent exercise program combining resistance, balance, and aerobic training at 50-60 minutes per session, 2-3 times per week. Meta-analyses show this reduces frailty prevalence (RR 0.76, 95% CI 0.65-0.89) and improves ADL performance (SMD 0.83) and gait speed (SMD 1.07).
  • •Prioritize mind-body training (e.g., Taiji, Baduanjin) as the most effective exercise modality for frailty reduction (SMD -0.71, 95% CI -1.22 to -0.21) and quality-of-life improvement (SMD 1.02). Aerobic training best enhances ADL performance (SMD 0.89). In institutionalized older adults, multicomponent programs achieve frailty reversal in 36% of participants, including those >85 years.
  • •Provide individualized nutritional support for malnourished frail patients: in hospitalized patients (EFFORT trial), protocol-guided nutrition targeting protein and energy goals reduced 30-day mortality from 13.6% to 7.1% (OR 0.48, 95% CI 0.31-0.76; NNT = 16). Screen using Nutritional Risk Screening 2002 ≥3 and intervene with a tailored plan.
  • •For frail or pre-frail surgical candidates, offer prehabilitation (multicomponent exercise, nutrition, psychosocial support) if surgery can be delayed 4-6 weeks. Prehabilitation is cost-effective when at least 15 sessions are completed (ICER €27,197 per prevented deterioration; 69% probability cost-effective at €50,000/QALY).
  • •Consider neuromuscular electrical stimulation (NMES) as a bridging option for patients who cannot participate in active exercise (e.g., after acute MI with PCI): apply 30 minutes daily to bilateral quadriceps and gastrocnemius for 7 days postoperatively to reduce frailty scores and improve lower limb strength (P < 0.001).
  • •Conduct medication reconciliation at every encounter; identify potentially inappropriate medications using Beers Criteria, STOPP/START, or EU(7)-PIM lists. Engage in shared decision-making with patient and caregivers regarding deprescribing.
  • •Initiate structured deprescribing for medications without clear benefit or with potential harm: taper gradually (especially benzodiazepines, anticholinergics, PPIs, antihypertensives) and monitor for withdrawal events within 4-6 weeks. The COFRAIL model (GP-led family conferences) reduced mean medications from 8.98 to 8.11 and EU(7)-PIMs from 1.30 to 1.71 at 6 months, though hospitalization rates did not differ.
  • •Avoid prescribing any single pharmacologic agent for frailty, testosterone, growth hormone, vitamin D alone, and anti-inflammatory drugs lack consistent evidence of benefit and may cause harm. No drug is approved for frailty syndrome.
  • •Screen for and treat depression: each additional point on the Geriatric Depression Scale increases odds of pre-frailty by 39% and frailty by 101%; depressive symptoms independently predict rapid cognitive decline (OR 3.10). Treat with appropriate antidepressants and non-pharmacologic supports.
  • •Implement fall prevention: prescribe the Otago Exercise Program (home-based strength and balance) which improves gait (WMD 0.49, 95% CI 0.18-0.80) and lower limb strength (WMD 0.84, 95% CI 0.61-1.07), with greatest benefit in those with compromised health. Ensure all indicated vaccinations (influenza, pneumococcal, COVID-19, herpes zoster) are administered.
  • •For patients with advanced frailty (CFS ≥7, recurrent hospitalization, severe disability), shift focus to comfort, symptom management, and advance care planning. Avoid aggressive treatments that are unlikely to improve quality of life. Coordinate multidisciplinary care involving geriatrician, pharmacist, physiotherapist, occupational therapist, and social worker for goal-concordant management.

Board Review — High Yield

  • •Fried phenotype, Frailty defined by ≥3 of 5 criteria: unintentional weight loss, exhaustion, weakness, slow gait, low physical activity. 1-2 criteria = pre-frail (reversible).
  • •Frailty Index, Alternative model counting accumulated deficits; >0.25 defines frailty. More sensitive to change but less practical.
  • •Weakness is first, Weakness is the most common initial manifestation, preceding other criteria in 76% of women who become frail.
  • •Inflammaging, Chronic low-grade IL-6, TNF-α elevation is central to frailty pathophysiology; NLRP3 inflammasome is key upstream activator.
  • •Multimodal exercise, Multicomponent exercise (resistance, balance, aerobic) reduces frailty prevalence (RR 0.76); mind-body training (Taiji, Baduanjin) most effective for frailty reduction (SMD -0.71).
  • •Nutritional support saves lives, In hospitalized frail patients, individualized nutrition reduces 30-day mortality from 13.6% to 7.1% (NNT=16).
  • •Deprescribing, Use Beers/STOPP criteria; family conferences can reduce medication count (COFRAIL trial: 8.98 to 8.11) though no reduction in hospitalizations.
  • •No drugs approved, No pharmacologic agent is approved for frailty; avoid testosterone, growth hormone, vitamin D alone.
  • •CFS + age >85 + devices, This combination explains 95% of delirium in acute care; triggers non-pharmacologic prevention bundles.
  • •Prehabilitation, Offer to pre-frail/frail surgical candidates; cost-effective if ≥15 sessions completed (ICER €27,197 per prevented deterioration).

Deep Dive — Evidence Details

References

  1. [1]

    Mourtzi N, Ntanasi E, Yannakoulia M et al.. “Apolipoprotein ε4 allele is associated with frailty syndrome: results from the hellenic longitudinal investigation of ageing and diet study.” Age and ageing (2019). PMID: 31504089 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 7. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History, 12. Special Populations and End-of-Life Context
  2. [2]

    Fairhall N, Aggar C, Kurrle SE et al.. “Frailty Intervention Trial (FIT).” BMC geriatrics (2008). PMID: 18851754 ↗

    L2RCTCited in: 1. Definition, Classification and Nomenclature, 9. Long-term and Definitive Management, History and Evolution of Treatment
  3. [3]

    Covell MM, Roy JM, Rumalla K et al.. “The Limited Utility of the Hospital Frailty Risk Score as a Frailty Assessment Tool in Neurosurgery: A Systematic Review.” Neurosurgery (2023). PMID: 37695046 ↗

    L2SR_OBSCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, History and Evolution of Treatment, 11. Prognosis and Natural History
  4. [4]

    Vaughan L, Corbin AL, Goveas JS. “Depression and frailty in later life: a systematic review.” Clinical interventions in aging (2015). PMID: 26719681 ↗

    L2SR_OBSCited in: 1. Definition, Classification and Nomenclature
  5. [5]

    Yoshimatsu Y, Thomas H, Thompson T et al.. “Prognostic factors of poor outcomes in pneumonia in older adults: aspiration or frailty?” European geriatric medicine (2024). PMID: 38310191 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored), 7. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations and End-of-Life Context
  6. [6]

    Cattaneo F, Buondonno I, Cravero D et al.. “Musculoskeletal Diseases Role in the Frailty Syndrome: A Case-Control Study.” International journal of environmental research and public health (2022). PMID: 36231199 ↗

    L3CASE_CONTROLCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors
  7. [7]

    Sepúlveda M, Palomo I, Montecino-Garrido H et al.. “Physiological changes associated with aging: Identification of novel biomarkers for frailty syndrome in women.” Free radical biology & medicine (2024). PMID: 39059511 ↗

    L4OTHERCited in: 1. Definition, Classification and Nomenclature
  8. [8]

    Zulfiqar AA, Andres E. “Assessment of the Zulfiqar Frailty Scale (ZFS) in Primary Healthcare.” Journal of clinical medicine (2024). PMID: 38930010 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature
  9. [9]

    Iacotucci P, Carnovale V, Ferrillo L et al.. “Cystic Fibrosis in Adults: A Paradigm of Frailty Syndrome? An Observational Study.” Journal of clinical medicine (2024). PMID: 38276090 ↗

    L4OTHERCited in: 1. Definition, Classification and Nomenclature
  10. [10]

    Kasiukiewicz A, Wojszel ZB. “The Prevalence of the Frailty Syndrome in a Hospital Setting-Is Its Diagnosis a Challenge? A Comparison of Four Frailty Scales in a Cross-Sectional Study.” Journal of clinical medicine (2023). PMID: 38202093 ↗

    L4OTHERCited in: 1. Definition, Classification and Nomenclature
  11. [11]

    Shardell M, Hicks GE, Miller RR et al.. “Association of low vitamin D levels with the frailty syndrome in men and women.” The journals of gerontology. Series A, Biological sciences and medical sciences (2009). PMID: 19164273 ↗

    L2OTHERCited in: 1. Definition, Classification and Nomenclature
  12. [12]

    Ble A, Cherubini A, Volpato S et al.. “Lower plasma vitamin E levels are associated with the frailty syndrome: the InCHIANTI study.” The journals of gerontology. Series A, Biological sciences and medical sciences (2006). PMID: 16567378 ↗

    L2OTHERCited in: 2. Pathophysiology and Mechanism (with ageing biology)
  13. [13]

    Locatelli E, Torsello B, De Marco S et al.. “Mitochondrial dysfunction as a biomarker of frailty: The FRAMITO study protocol.” Archives of gerontology and geriatrics (2025). PMID: 40043348 ↗

    L5TRIAL_NONRANDOMCited in: 2. Pathophysiology and Mechanism (with ageing biology), 3. Epidemiology, Etiology and Risk Factors, 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care
  14. [14]

    Chen X, Mao G, Leng SX. “Frailty syndrome: an overview.” Clinical interventions in aging (2014). PMID: 24672230 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism (with ageing biology)
  15. [15]

    Fried LP, Cohen AA, Xue QL et al.. “The physical frailty syndrome as a transition from homeostatic symphony to cacophony.” Nature aging (2021). PMID: 34476409 ↗

    L5OTHERCited in: 2. Pathophysiology and Mechanism (with ageing biology)
  16. [16]

    Sánchez Y Sánchez de la Barquera B, Martínez Carrillo BE, Aguirre Garrido JF et al.. “Emerging Evidence on the Use of Probiotics and Prebiotics to Improve the Gut Microbiota of Older Adults with Frailty Syndrome: A Narrative Review.” The journal of nutrition, health & aging (2022). PMID: 36259581 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism (with ageing biology)
  17. [17]

    Seymour F, Carmichael J, Taylor C et al.. “Immune senescence in multiple myeloma-a role for mitochondrial dysfunction?” Leukemia (2022). PMID: 35879358 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism (with ageing biology)
  18. [18]

    Bogucka D, Wajda A, Stypińska B et al.. “Epigenetic factors and inflammaging: FOXO3A as a potential biomarker of sarcopenia and upregulation of DNMT3A and SIRT3 in older adults.” Frontiers in immunology (2025). PMID: 40034697 ↗

    L4OTHERCited in: 2. Pathophysiology and Mechanism (with ageing biology)
  19. [19]

    Crooke A, Martínez-Alberquilla I, García-Montero M et al.. “Impact of contact lens wear on NLRP3 gene expression: Implications for ocular frailty in middle-aged adults.” Experimental eye research (2020). PMID: 33197452 ↗

    L3REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism (with ageing biology)
  20. [20]

    Wacka E, Wawrzyniak-Gramacka E, Tylutka A et al.. “The Role of Inflammation in Age-Associated Changes in Red Blood System.” International journal of molecular sciences (2023). PMID: 37240288 ↗

    L4OTHERCited in: 2. Pathophysiology and Mechanism (with ageing biology)
  21. [21]

    Freitas WM, Carvalho LS, Moura FA et al.. “Atherosclerotic disease in octogenarians: a challenge for science and clinical practice.” Atherosclerosis (2012). PMID: 22858284 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism (with ageing biology)
  22. [22]

    Santos CAF, Amirato GR, Paixão V et al.. “Association among inflammaging, body composition, physical activity, and physical function tests in physically active women.” Frontiers in medicine (2023). PMID: 37534321 ↗

    L4OTHERCited in: 2. Pathophysiology and Mechanism (with ageing biology)
  23. [23]

    Xu Y, Mao T, Wang Y et al.. “Effect of Gut Microbiota-Mediated Tryptophan Metabolism on Inflammaging in Frailty and Sarcopenia.” The journals of gerontology. Series A, Biological sciences and medical sciences (2024). PMID: 38366346 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism (with ageing biology)
  24. [24]

    Bombelli S, Grasselli C, Mazzola P et al.. “Impairment of Renal and Hematopoietic Stem/Progenitor Cell Compartments in Frailty Syndrome: Link With Oxidative Stress, Plasma Cytokine Profiles, and Nuclear DNA Damage.” The journals of gerontology. Series A, Biological sciences and medical sciences (2024). PMID: 39066510 ↗

    L3OTHERCited in: 2. Pathophysiology and Mechanism (with ageing biology)
  25. [25]

    Burton JK, Stewart J, Blair M et al.. “Prevalence and implications of frailty in acute stroke: systematic review & meta-analysis.” Age and ageing (2022). PMID: 35352795 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 7. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations and End-of-Life Context
  26. [26]

    Kolehmainen L, Havulinna S, Ngandu T et al.. “Earlier life leisure-time physical activity in relation to age-related frailty syndrome.” Age and ageing (2021). PMID: 32808971 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 12. Special Populations and End-of-Life Context
  27. [27]

    Cesari M, Vellas B, Hsu FC et al.. “A physical activity intervention to treat the frailty syndrome in older persons-results from the LIFE-P study.” The journals of gerontology. Series A, Biological sciences and medical sciences (2014). PMID: 25387728 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 7. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care, 12. Special Populations and End-of-Life Context
  28. [28]

    Tompkins BA, DiFede DL, Khan A et al.. “Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial.” The journals of gerontology. Series A, Biological sciences and medical sciences (2017). PMID: 28977399 ↗

    L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), History and Evolution of Treatment, 12. Special Populations and End-of-Life Context
  29. [29]

    Silveira BD, Farias E Farias A, Brum V et al.. “Breaking the frailty cycle with rehabilitation programs. A systematic review and meta-analysis of randomized controlled trials.” Disability and rehabilitation (2025). PMID: 39917808 ↗

    L1SR_MA_RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 9. Long-term and Definitive Management
  30. [30]

    Xue QL, Bandeen-Roche K, Varadhan R et al.. “Initial manifestations of frailty criteria and the development of frailty phenotype in the Women's Health and Aging Study II.” The journals of gerontology. Series A, Biological sciences and medical sciences (2008). PMID: 18840805 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), History and Evolution of Treatment, 11. Prognosis and Natural History, 12. Special Populations and End-of-Life Context
  31. [31]

    Kurpesa M, Słomka S, Lipiec P et al.. “Arrhythmias and conduction disturbances in elderly patients, including frailty syndrome. An expert opinion statement from the Working Group on Cardiac Rehabilitation and Exercise Physiology of the Polish Cardiac Society.” Kardiologia polska (2025). PMID: 40899359 ↗

    L5GUIDELINECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored), 9. Long-term and Definitive Management, History and Evolution of Treatment, 12. Special Populations and End-of-Life Context
  32. [32]

    Swarbrick CJ, Blake HA, Martin P et al.. “Directed acyclic graphs to minimise bias and optimise causal inference in SNAP-3: an observational cohort study of frailty, multimorbidity, and delirium in older surgical patients.” British journal of anaesthesia (2025). PMID: 40425394 ↗

    L5COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 7. Severity, Staging and Risk Stratification, 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care, 11. Prognosis and Natural History
  33. [33]

    Shamsalinia A, Hosseini SR, Bijani A et al.. “Cardiovascular disease risk factors and frailty syndrome in community-dwelling older adults: Results from the Amirkola Health and Aging Project Cohort Study.” BMC geriatrics (2024). PMID: 39117995 ↗

    L4COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored), 11. Prognosis and Natural History, 13. Prevention, Screening and Surveillance
  34. [34]

    Kim N, Kim GS, Won CW et al.. “Two-year longitudinal associations between nutritional status and frailty in community-dwelling older adults: Korean Frailty and Aging Cohort Study.” BMC geriatrics (2023). PMID: 37020292 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  35. [35]

    Ortiz J, Solano MT, Gallego C et al.. “At-home autologous hematopoietic cell transplant for adults with hematological malignancies. How frailty impacts and evolves during HCT procedure. An observational, longitudinal, and prospective study.” Cancer treatment and research communications (2025). PMID: 40215761 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored)
  36. [36]

    Rocha VTM, Leopoldino AAO, de Queiroz BZ et al.. “The impact of low back pain and disability on frailty levels in older women: longitudinal data from the BACE-Brazil cohort.” European geriatric medicine (2023). PMID: 36622621 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 12. Special Populations and End-of-Life Context
  37. [37]

    Ticinesi A, Parise A, Delmonte D et al.. “Factors associated with delirium in a real-world acute-care setting: analysis considering the interdependence of clinical variables with the frailty syndrome.” European geriatric medicine (2024). PMID: 38329618 ↗

    L4OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored), 8. Acute Care and Prevention of Hospital-Associated Harm, 12. Special Populations and End-of-Life Context
  38. [38]

    Encarnação SG, Martinez WAL, Martínez-Ferrán M et al.. “Correlation Between Objectively Measured Spontaneous Physical Activity and Sedentary Behavior With Frailty Syndrome in Older Adults: A Systematic Review and Meta-Analysis of Observational Studies.” Journal of aging research (2026). PMID: 42253316 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored)
  39. [39]

    Shang S, Yang L, Zhang Q et al.. “Prevalence of frailty in hemodialysis patients and its impact on long-term survival in elderly hemodialysis patients.” Frontiers in medicine (2026). PMID: 42305955 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored), 7. Severity, Staging and Risk Stratification, 13. Prevention, Screening and Surveillance
  40. [40]

    Shardell M, Semba RD, Kalyani RR et al.. “Plasma Klotho and Frailty in Older Adults: Findings From the InCHIANTI Study.” The journals of gerontology. Series A, Biological sciences and medical sciences (2019). PMID: 29053774 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors
  41. [41]

    Navarro-Martínez R, Serrano-Carrascosa M, Buigues C et al.. “Frailty syndrome is associated with changes in peripheral inflammatory markers in prostate cancer patients undergoing androgen deprivation therapy.” Urologic oncology (2019). PMID: 31521528 ↗

    L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation
  42. [42]

    Liu G, Ge R, Zhu H. “Mind-body training outperforms other physical activities in reducing frailty and enhancing quality of life in older adults: a network meta-analysis.” Frontiers in public health (2025). PMID: 40726938 ↗

    L1SR_OBSCited in: 4. Clinical Presentation, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 9. Long-term and Definitive Management, 11. Prognosis and Natural History, 12. Special Populations and End-of-Life Context
  43. [43]

    Dobrzycka M, Wołoszyn P, Prud M et al.. “Long-Term Functional Outcomes After Prehabilitation in Frail Older Adults Undergoing Colorectal Cancer Surgery: A One-Year Prospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42355899 ↗

    L2COHORTCited in: 4. Clinical Presentation, 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored), 7. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations and End-of-Life Context
  44. [44]

    Wołoszyn-Horák E, Salamon R, Chojnacka K et al.. “Frailty syndrome in daily practice of interventional cardiology ward-rationale and design of the FRAPICA trial: A STROBE-compliant prospective observational study.” Medicine (2020). PMID: 32000408 ↗

    L5TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 7. Severity, Staging and Risk Stratification, 9. Long-term and Definitive Management
  45. [45]

    Chang Z, Cao X, Zhang X et al.. “Depressive symptoms and cognitive function trajectories in frail middle-aged and older adults: A longitudinal analysis based on the CHARLS cohort (2011-2018).” General hospital psychiatry (2025). PMID: 40812043 ↗

    L2OTHERCited in: 4. Clinical Presentation, 13. Prevention, Screening and Surveillance
  46. [46]

    Wleklik M, Lee CS, Jędrzejczyk M et al.. “Association of education level and depression with cognitive decline: findings from the examining cognitive health outcomes in heart failure study.” Frontiers in cardiovascular medicine (2025). PMID: 40364822 ↗

    L2OTHERCited in: 4. Clinical Presentation
  47. [47]

    Chow KL, Keating PE, Solanki K et al.. “Anti-HMGCR myopathy: Diversity of clinical presentations in a national cohort in New Zealand.” Seminars in arthritis and rheumatism (2024). PMID: 39079206 ↗

    L4OTHERCited in: 4. Clinical Presentation
  48. [48]

    Vankova H, Schmalz M, Andel R et al.. “Frailty and depressive symptoms in older kidney transplant recipients: opportunities for collaboration between transplant nephrologists and geriatricians.” BMC geriatrics (2024). PMID: 38741066 ↗

    L4OTHERCited in: 4. Clinical Presentation
  49. [49]

    Arking DE, Fallin DM, Fried LP et al.. “Variation in the ciliary neurotrophic factor gene and muscle strength in older Caucasian women.” Journal of the American Geriatrics Society (2006). PMID: 16696750 ↗

    L4OTHERCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 12. Special Populations and End-of-Life Context
  50. [50]

    Rombey T, Eckhardt H, Quentin W et al.. “Cost-effectiveness of prehabilitation for elderly (pre-)frail patients prior to elective surgery compared to standard care - an economic evaluation from a societal perspective.” BMC medicine (2026). PMID: 42163295 ↗

    L1RCTCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored), 9. Long-term and Definitive Management, History and Evolution of Treatment, 12. Special Populations and End-of-Life Context
  51. [51]

    Nguyen LT, Nguyen KT, Dao LTM et al.. “Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial.” EBioMedicine (2026). PMID: 42019090 ↗

    L1RCTCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), History and Evolution of Treatment, 12. Special Populations and End-of-Life Context
  52. [52]

    Schöne C, Fuchs TI, Kiselev J et al.. “Facilitators and barriers to participation in prehabilitation prior to orthopaedic elective surgery - a qualitative study with elderly (pre-)frail patients.” BMC geriatrics (2025). PMID: 41188708 ↗

    L5RCTCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), History and Evolution of Treatment, 12. Special Populations and End-of-Life Context
  53. [53]

    Michelon E, Blaum C, Semba RD et al.. “Vitamin and carotenoid status in older women: associations with the frailty syndrome.” The journals of gerontology. Series A, Biological sciences and medical sciences (2006). PMID: 16799143 ↗

    L4OTHERCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 12. Special Populations and End-of-Life Context
  54. [54]

    von Känel R, Dimsdale JE, Mills PJ et al.. “Effect of Alzheimer caregiving stress and age on frailty markers interleukin-6, C-reactive protein, and D-dimer.” The journals of gerontology. Series A, Biological sciences and medical sciences (2006). PMID: 16960028 ↗

    L4OTHERCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), History and Evolution of Treatment, 11. Prognosis and Natural History, 12. Special Populations and End-of-Life Context
  55. [55]

    Wang C, Kim SM. “The Otago Exercise Program's effect on fall prevention: a systematic review and meta-analysis.” Frontiers in public health (2025). PMID: 40529705 ↗

    L1SR_OBSCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 12. Special Populations and End-of-Life Context, 13. Prevention, Screening and Surveillance
  56. [56]

    Zhang D, Zhang Q, Xiao X et al.. “Blind nasoenteric tube insertion using a pharmaco-mechanical synergy protocol in frail older adults with chronic wounds: a retrospective study.” Frontiers in medicine (2026). PMID: 42422840 ↗

    L4COHORTCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 12. Special Populations and End-of-Life Context
  57. [57]

    Kreutzmann HPMMR, Palm P, Rasmussen TB et al.. “The association between self-reported frailty status and 1-year all-cause mortality and readmission following PCI: A prospective multi-centre cohort study, CONCARDPCI.” International journal of cardiology (2025). PMID: 41354156 ↗

    L2COHORTCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 7. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History
  58. [58]

    Kotsani M, Avgerinou C, Haidich AB et al.. “Feasibility and impact of a short training course on frailty destined for primary health care professionals.” European geriatric medicine (2021). PMID: 33646537 ↗

    L4OTHERCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored), 12. Special Populations and End-of-Life Context, 13. Prevention, Screening and Surveillance
  59. [59]

    Robertson DA, Savva GM, Coen RF et al.. “Cognitive function in the prefrailty and frailty syndrome.” Journal of the American Geriatrics Society (2014). PMID: 25370593 ↗

    L4OTHERCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored), History and Evolution of Treatment, 12. Special Populations and End-of-Life Context
  60. [60]

    Shah K, Hilton TN, Myers L et al.. “A new frailty syndrome: central obesity and frailty in older adults with the human immunodeficiency virus.” Journal of the American Geriatrics Society (2012). PMID: 22315957 ↗

    L4OTHERCited in: 5. Geriatric Syndromes and the Cascade to Disability (Falls and Gait Instability, Delirium, Incontinence, Immobility, Frailty, Pressure Injury), 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored), 12. Special Populations and End-of-Life Context
  61. [61]

    Kamińska A, Bonczar M, Plutecki D et al.. “Postoperative Complications in Patients with Frailty Syndrome Undergoing Esophagectomy-A Systematic Review with Meta-Analysis.” Journal of clinical medicine (2026). PMID: 42074841 ↗

    L2SR_OBSCited in: 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored)
  62. [62]

    Sepúlveda M, Palomo I, Lagos F et al.. “Biomarkers of oxidative damage as a tool to investigate frailty syndrome in older women.” npj aging (2026). PMID: 41942466 ↗

    L4OTHERCited in: 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored)
  63. [63]

    Bujnowska-Fedak MM, Sobieski M, Fedak A et al.. “The ActivLife exergame rehabilitation program improves functional abilities in pre-frail and frail older adults: a clinical trial.” Scientific reports (2026). PMID: 41796126 ↗

    L2TRIAL_NONRANDOMCited in: 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored)
  64. [64]

    Krzeszowiak J, Wróbel S, Del Carmen Yika A et al.. “Evaluation of individual and composite CT-based markers in frailty diagnostics in older patients with cancer undergoing major abdominal surgery.” BMC geriatrics (2025). PMID: 41361257 ↗

    L4OTHERCited in: 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored)
  65. [65]

    Yang H, Xiao J, Zhang W et al.. “Sex Differences in the Association Between Inflammatory Biomarkers (Hs-CRP, IL-6, IL-10, TNF-α) and Frailty in Hospitalized Adults Aged ≥65 in Taizhou, China: A Cross-Sectional Study.” Clinical interventions in aging (2025). PMID: 41357993 ↗

    L4OTHERCited in: 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored)
  66. [66]

    Sánchez-Flores M, Marcos-Pérez D, Lorenzo-López L et al.. “Frailty Syndrome and Genomic Instability in Older Adults: Suitability of the Cytome Micronucleus Assay As a Diagnostic Tool.” The journals of gerontology. Series A, Biological sciences and medical sciences (2018). PMID: 29346525 ↗

    L4OTHERCited in: 6. Diagnosis and Workup (Comprehensive Geriatric Assessment-anchored), 11. Prognosis and Natural History
  67. [67]

    Navarrete-Villanueva D, Gómez-Cabello A, Marín-Puyalto J et al.. “Frailty and Physical Fitness in Elderly People: A Systematic Review and Meta-analysis.” Sports medicine (Auckland, N.Z.) (2021). PMID: 33201455 ↗

    L2SR_OBSCited in: 7. Severity, Staging and Risk Stratification, 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care
  68. [68]

    Shamsalinia A, Hosseini SR, Bijani A et al.. “Effects of Frailty Syndrome on Osteoporosis, Focusing on the Mediating Effect of Muscle Strength and Balance in Community-Dwelling Older Adults (≥60 years) in Iran: Results From the Amirkola Health and Aging Project Cohort Study.” Geriatric orthopaedic surgery & rehabilitation (2024). PMID: 39070931 ↗

    L4COHORTCited in: 7. Severity, Staging and Risk Stratification
  69. [69]

    Brunelli L, Davin A, Sestito G et al.. “Plasmatic Hippuric Acid as a Hallmark of Frailty in an Italian Cohort: The Mediation Effect of Fruit-Vegetable Intake.” The journals of gerontology. Series A, Biological sciences and medical sciences (2021). PMID: 34436596 ↗

    L4OTHERCited in: 7. Severity, Staging and Risk Stratification
  70. [70]

    Luong R, Ribeiro RV, Rangan A et al.. “Changes in Dietary Total and Nonheme Iron Intake Is Associated With Incident Frailty in Older Men: The Concord Health and Aging in Men Project.” The journals of gerontology. Series A, Biological sciences and medical sciences (2022). PMID: 35352124 ↗

    L2OTHERCited in: 7. Severity, Staging and Risk Stratification
  71. [71]

    Bilotta C, Nicolini P, Casè A et al.. “Frailty syndrome diagnosed according to the Study of Osteoporotic Fractures (SOF) criteria and adverse health outcomes among community-dwelling older outpatients in Italy. A one-year prospective cohort study.” Archives of gerontology and geriatrics (2011). PMID: 21871675 ↗

    L2COHORTCited in: 8. Acute Care and Prevention of Hospital-Associated Harm
  72. [72]

    Bilotta C, Bowling A, Nicolini P et al.. “Older People's Quality of Life (OPQOL) scores and adverse health outcomes at a one-year follow-up. A prospective cohort study on older outpatients living in the community in Italy.” Health and quality of life outcomes (2011). PMID: 21892954 ↗

    L2COHORTCited in: 8. Acute Care and Prevention of Hospital-Associated Harm
  73. [73]

    Kennedy CA, Shipway D, Barry K. “Frailty and emergency abdominal surgery: A systematic review and meta-analysis.” The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland (2021). PMID: 34980559 ↗

    L2SR_OBSCited in: 8. Acute Care and Prevention of Hospital-Associated Harm
  74. [74]

    Hammami S, Zarrouk A, Piron C et al.. “Prevalence and factors associated with frailty in hospitalized older patients.” BMC geriatrics (2020). PMID: 32306905 ↗

    L4OTHERCited in: 8. Acute Care and Prevention of Hospital-Associated Harm
  75. [75]

    Swarbrick CJ, Williams K, Evans B et al.. “SNAP-3: characteristics of specific subgroups of older patients undergoing surgery in the UK.” British journal of anaesthesia (2025). PMID: 40908181 ↗

    L2OTHERCited in: 8. Acute Care and Prevention of Hospital-Associated Harm, 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care
  76. [76]

    Viswanath M, Clinch D, Ceresoli M et al.. “Perceptions and practices surrounding the perioperative management of frail emergency surgery patients: a WSES-endorsed cross-sectional qualitative survey.” World journal of emergency surgery : WJES (2023). PMID: 36653865 ↗

    L4OTHERCited in: 8. Acute Care and Prevention of Hospital-Associated Harm
  77. [77]

    Abbatecola AM, Incalzi RA, Malara A et al.. “Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study.” Vaccine (2022). PMID: 35248424 ↗

    L5OTHERCited in: 8. Acute Care and Prevention of Hospital-Associated Harm
  78. [78]

    Soong J, Poots AJ, Scott S et al.. “Developing and validating a risk prediction model for acute care based on frailty syndromes.” BMJ open (2015). PMID: 26490098 ↗

    L3OTHERCited in: 8. Acute Care and Prevention of Hospital-Associated Harm
  79. [79]

    Uchmanowicz I, Gobbens RJ. “The relationship between frailty, anxiety and depression, and health-related quality of life in elderly patients with heart failure.” Clinical interventions in aging (2015). PMID: 26491276 ↗

    L4OTHERCited in: 8. Acute Care and Prevention of Hospital-Associated Harm
  80. [80]

    Singh DK, Ganesh V, Sahni N et al.. “Prevalence of frailty and its effect on requirement of organ support and clinical outcomes in critically ill patients: a prospective observational single center study.” BMC anesthesiology (2025). PMID: 40287615 ↗

    L2OTHERCited in: 8. Acute Care and Prevention of Hospital-Associated Harm
  81. [81]

    Ormazábal Y, Arauna D, Cantillana JC et al.. “Unveiling the Frailty Spatial Patterns Among Chilean Older Persons by Exploring Sociodemographic and Urbanistic Influences Based on Geographic Information Systems: Cross-Sectional Study.” JMIR aging (2025). PMID: 40245404 ↗

    L4OTHERCited in: 8. Acute Care and Prevention of Hospital-Associated Harm
  82. [82]

    Pu X, Huang H, Zhao X et al.. “Improving Lower Limb Function and Frailty in Frail Older Patients with Acute Myocardial Infarction After Percutaneous Coronary Intervention: A Randomized Controlled Study of Neuromuscular Electrical Stimulation.” Clinical interventions in aging (2024). PMID: 38974513 ↗

    L1RCTCited in: 9. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History
  83. [83]

    Baumgartner A, Pachnis D, Parra L et al.. “The impact of nutritional support on malnourished inpatients with aging-related vulnerability.” Nutrition (Burbank, Los Angeles County, Calif.) (2021). PMID: 34090212 ↗

    L2RCTCited in: 9. Long-term and Definitive Management, 13. Prevention, Screening and Surveillance
  84. [84]

    Rossi PG, Carnavale BF, Farche ACS et al.. “Effects of physical exercise on the cognition of older adults with frailty syndrome: A systematic review and meta-analysis of randomized trials.” Archives of gerontology and geriatrics (2020). PMID: 33360014 ↗

    L1SR_OBSCited in: 9. Long-term and Definitive Management
  85. [85]

    Martínez-Montas GF, Sanz-Matesanz M, Benítez-Sillero JD et al.. “Prevention and Mitigation of Frailty Syndrome in Institutionalised Older Adults Through Physical Activity: A Systematic Review.” Healthcare (Basel, Switzerland) (2025). PMID: 39942466 ↗

    L2SR_OBSCited in: 9. Long-term and Definitive Management, 13. Prevention, Screening and Surveillance
  86. [86]

    Karagül S, Kibar S, Ay S et al.. “THE EFFECT OF A 6-WEEK BALANCE EXERCISE PROGRAM ON BALANCE PARAMETERS IN FRAILTY SYNDROME: A RANDOMIZED CONTROLLED, DOUBLE-BLIND, PROSPECTIVE STUDY.” Georgian medical news (2023). PMID: 38325295 ↗

    L1RCTCited in: 9. Long-term and Definitive Management
  87. [87]

    Holmes HM, Beck MS, Rowe JH. “Geriatrics: Year in review.” Journal of geriatric oncology (2016). PMID: 27313081 ↗

    L5REVIEW_NARRATIVECited in: 9. Long-term and Definitive Management
  88. [88]

    Schmaltz HN, Fried LP, Xue QL et al.. “Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women.” Journal of the American Geriatrics Society (2005). PMID: 15877548 ↗

    L4OTHERCited in: History and Evolution of Treatment
  89. [89]

    Kasa AS, Drury P, Traynor V et al.. “The effectiveness of nurse-led interventions to manage frailty in community-dwelling older people: a systematic review.” Systematic reviews (2023). PMID: 37777786 ↗

    L2SR_OBSCited in: History and Evolution of Treatment
  90. [90]

    Mortsiefer A, Löscher S, Pashutina Y et al.. “Family Conferences to Facilitate Deprescribing in Older Outpatients With Frailty and With Polypharmacy: The COFRAIL Cluster Randomized Trial.” JAMA network open (2023). PMID: 36972052 ↗

    L1RCTCited in: History and Evolution of Treatment, 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care, 11. Prognosis and Natural History
  91. [91]

    Roschel H, Hayashi AP, Fernandes AL et al.. “Supplement-based nutritional strategies to tackle frailty: A multifactorial, double-blind, randomized placebo-controlled trial.” Clinical nutrition (Edinburgh, Scotland) (2021). PMID: 34358827 ↗

    L1RCTCited in: History and Evolution of Treatment
  92. [92]

    Sanders NA, Supiano MA, Lewis EF et al.. “The frailty syndrome and outcomes in the TOPCAT trial.” European journal of heart failure (2018). PMID: 30225878 ↗

    L2RCTCited in: History and Evolution of Treatment
  93. [93]

    Buigues C, Fernández-Garrido J, Pruimboom L et al.. “Effect of a Prebiotic Formulation on Frailty Syndrome: A Randomized, Double-Blind Clinical Trial.” International journal of molecular sciences (2016). PMID: 27314331 ↗

    L1RCTCited in: History and Evolution of Treatment
  94. [94]

    Haren A, Lal R, Walker D et al.. “Frailty assessment in older urological patients prior to surgery: a systematic review and narrative synthesis.” Therapeutic advances in urology (2020). PMID: 32435276 ↗

    L2SR_OBSCited in: 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care
  95. [95]

    Buigues C, Juarros-Folgado P, Fernández-Garrido J et al.. “Frailty syndrome and pre-operative risk evaluation: A systematic review.” Archives of gerontology and geriatrics (2015). PMID: 26272286 ↗

    L2SR_OBSCited in: 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care
  96. [96]

    Swarbrick CJ, Williams K, Evans B et al.. “Postoperative outcomes in older patients living with frailty and multimorbidity in the UK: SNAP-3, a snapshot observational study.” British journal of anaesthesia (2025). PMID: 40425395 ↗

    L2OTHERCited in: 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care
  97. [97]

    Mirkowski K, Vellone E, Żółkowska B et al.. “Frailty and Heart Failure: Clinical Insights, Patient Outcomes and Future Directions.” Cardiac failure review (2025). PMID: 40083651 ↗

    L5REVIEW_NARRATIVECited in: 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care
  98. [98]

    Paraskevopoulos A, Wettermark B, Tsiligianni I. “Factors Influencing General Practitioners' Deprescribing Decisions for Older Adults, with Insights into Frailty: a Qualitative Study in Greek Primary Care.” Drugs & aging (2025). PMID: 39984778 ↗

    L4OTHERCited in: 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care
  99. [99]

    Uchmanowicz I, Faulkner KM, Iovino P et al.. “Integrating frailty interventions into existing care models: a comprehensive approach to enhancing patient outcomes in chronic disease management.” Frontiers in public health (2025). PMID: 39906402 ↗

    L5REVIEW_NARRATIVECited in: 10. Multimorbidity, Polypharmacy, Deprescribing and Goals of Care
  100. [100]

    Ara R, Monisha UK, Nova TJ et al.. “Potential nonpharmacological interventions to prevent frailty among elderly in low- and middle-income countries: A protocol for systematic review.” Medicine (2022). PMID: 35089233 ↗

    L5SR_OBSCited in: 13. Prevention, Screening and Surveillance
  101. [101]

    Lomper K, Jędrzejczyk M, Wleklik M et al.. “Relationship of malnutrition and frailty on prolonged stay at the hospital in heart failure patients.” ESC heart failure (2025). PMID: 40785522 ↗

    L4OTHERCited in: 13. Prevention, Screening and Surveillance

Revision History

All updates applied to this page

Loading revisions…